1,510
Participants
Start Date
August 26, 2016
Primary Completion Date
October 15, 2020
Study Completion Date
October 15, 2020
Apixaban
"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~\- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
Standard of care
VKA or Antiplatelet therapy
Unità Operativa di Cardiologia Fondazione Gabriele Monasterio C.N.R., Massa
ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC, Paris
Division of Cardiology and Angiology II, University Heart Center Freiburg, Bad Krozingen
Hospitalet de Llobregat-Hospital Universitari de Bellvitge, Barcelona
Collaborators (2)
Action Research Group
OTHER
Bristol-Meyers Squibb & Pfizer
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER